Retatrutide is a synthetic research peptide studied for triple hormone receptor agonism — activity across the GLP-1, GIP, and glucagon receptors within a single molecule. Originally advanced through Eli Lilly's clinical research pipeline, it has become one of the most closely watched compounds in metabolic and endocrine research because of that three-receptor mechanism, which sets it apart from single- or dual-agonist peptides such as semaglutide and tirzepatide. Helix Bio supplies Retatrutide as a lyophilized powder intended strictly for laboratory and preclinical research, manufactured to a high-purity standard and backed by third-party verification. It is not intended for human consumption, diagnostic use, or any therapeutic application.
HPLC certified
Independent analysis
Highest standard
Full traceability
Retatrutide belongs to a newer class of incretin-based peptides studied for activity across three separate metabolic receptor pathways rather than one or two. Earlier compounds such as liraglutide and semaglutide act on the GLP-1 receptor alone, and tirzepatide adds GIP receptor activity on top of that. Retatrutide is studied for engaging GLP-1, GIP, and glucagon receptors concurrently — the "triple agonist" profile that draws so much attention from researchers working on metabolic rate, appetite regulation, and glucose homeostasis models.
Helix Bio's Retatrutide is supplied as a lyophilized (freeze-dried) powder — a single-chain synthetic peptide manufactured under controlled laboratory conditions. Lyophilization extends the peptide's shelf stability prior to reconstitution, which matters for labs that don't use a full vial in one sitting.
This product exists to support in vitro and preclinical laboratory research only. It's manufactured, labeled, and sold for research use only (RUO) — not for human or veterinary use, not for diagnostic procedures, and not for compounding. It's intended for researchers studying incretin pharmacology, receptor binding behavior, or metabolic research models.
Sourcing a research peptide comes down to trust — trust in what's actually in the vial, trust in the paperwork behind it, and trust that the supplier understands the compound well enough to represent it accurately. Retatrutide is a molecule researchers are watching closely right now, precisely because its three-receptor mechanism sets it apart from the GLP-1-only and dual-agonist peptides that have dominated metabolic research for years. Helix Bio manufactures its Retatrutide domestically, backs every batch with purity testing, and provides documentation so researchers can evaluate what they're working with before it reaches the bench. If your protocol calls for a triple agonist peptide with a clear paper trail, that's what this listing is built around.
This product is not intended for individual consumers seeking to use it outside a research setting.
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Cyclic peptides resist protease degradation and reach undruggable targets. Learn how peptide cyclization works and why stability improves. Explore the research.
How continuous flow, automation, enzymatic routes and AI are changing peptide synthesis technology, and what it means for research peptide purity and supply.
AI now designs peptides from scratch. How AlphaFold 3, RFdiffusion and protein language models reshaped peptide discovery in 2026 — research use only.
